The in vitro red blood cell (RBC) agglutination assay, or hemagglutination assay, remains a cornerstone of immunological and hematological research. Its principle is elegantly simple yet profoundly powerful: the multivalent binding of an agent—be it an antibody, a lectin, or an engineered protein—to antigens on the surface of multiple RBCs, resulting in a macroscopically visible lattice of clumped cells. This phenomenon provides a direct, visual readout of a specific molecular interaction.
Furthermore, hemagglutination assays are pivotal in drug discovery and development, particularly for screening and characterizing inhibitors of carbohydrate-binding proteins like galectins. By quantifying the inhibition of galectin induced RBC agglutination, researchers can effectively determine the potency and selectivity of small-molecule glycomimetic drugs, which hold therapeutic promise in oncology and inflammatory diseases. The assay is also a critical tool in preclinical safety assessment, used to evaluate the hemocompatibility of novel therapeutics, polymers, and biomaterials.
Fig.1 Galectin-3 induced hemagglutination in human red blood cells.1
At Creative Biolabs, we have refined the classic hemagglutination assay into a robust, high-precision quantitative platform. With over two decades of specialized experience, we recognize that modern therapeutic and diagnostic development demands more than a qualitative yes/no answer. Our platform is engineered to deliver precise, reproducible, and highly granular data suitable for advanced research and regulatory submissions.
We have moved beyond simple visual inspection by integrating state-of-the-art imaging and analysis technologies. Our standard protocol utilizes U-bottom microplates, which facilitate the formation of distinct, analyzable RBC pellets or agglutination patterns. These plates are then imaged using high-resolution scanners, and the results are quantified using sophisticated image analysis software. This approach allows us to:
Our expertise extends to managing the complex variables that can influence assay outcomes. We have characterized the differential agglutination efficacy of agents across various blood groups (O, A, B), a critical consideration for developing therapeutics with broad applicability. We also systematically evaluate the modulatory effects of plasma proteins, as albumin and other components can significantly alter the activity of test agents, sometimes protectively, sometimes synergistically.
When you partner with Creative Biolabs, you gain access to a comprehensive service package designed to provide actionable insights. Our service is not a one-size-fits-all offering; it is tailored to your specific research objectives.
Our Core Service Content Includes:
Choosing Creative Biolabs provides a distinct advantage rooted in our commitment to scientific rigor and client success.
We can test a wide range of purified samples, including proteins, antibodies, peptides, small molecules, and polymers. Please provide them in a suitable buffer with concentration and purity information.
Yes. Creative Biolabs maintains a supply of cryopreserved RBCs from various blood groups and can source or produce a wide array of agglutinating agents, including recombinant galectins and specific antibodies.
Our imaging-based analysis of U-bottom plates has been shown to be superior to absorbance readings from flat-bottom plates for quantifying hemagglutination. It provides a more direct and sensitive measurement of cell clumping, avoiding artifacts from cell settling and offering a wider dynamic range.
Advance your research with the precision and expertise of Creative Biolabs. To discuss your project needs or to request a quote for our In Vitro Red Blood Cell Agglutination Assay services, please contact our scientific team today.
Reference
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.